Results from First AML Genome Indicate More Data Needed to Provide Clinical Use

The remainder of the genome could harbor hundreds of other relevant mutations, and researchers and cancer experts believe a lot more tumor genomes need to be sequenced in order to understand the effect of these, and before doctors will be able to use the information to make clinical decisions.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.